Clinical and Experimental Therapeutics

Ratain, Mark

Abstract

This is a multifaceted program including (1) synthesis and preclinical evaluation of new antineoplastic agents, (2) mechanisms and modulation of resistance to cytotoxic drugs and radiation, (3) phase I clinical trials of new agents and treatment approaches and (4) clinical pharmacokinetics and pharmacodynamics of anticancer drugs. The Developmental Therapeutics Program brings together faculty in five Departments, two Committees, the Ben May Institute and the College, fostering collaborative research efforts. The Program has the capacity to develop drugs from initial synthesis through phase I clinical testing. The Developmental Therapeutics Program is also the primary user of the new Pharmacology Core Facility which will also be used in collaborative projects with both the Clinical Investigations and Immunology and Cancer Programs. The Program also serves as a resource for training in cancer pharmacology and antineoplastic drug development, and it is partially supported by training grants from the NIH.

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Cancer Institute (NCI)
• Type: Center Core Grants (P30)
• Project #: 2P30CA014599-23
• Application #: 5206668
• Support Year: 23
• Fiscal Year: 1996

Publications

Sample, Ashley; He, Yu-Ying (2018) Mechanisms and prevention of UV-induced melanoma. Photodermatol Photoimmunol Photomed 34:13-24

Jeong, Choongwon; Witonsky, David B; Basnyat, Buddha et al. (2018) Detecting past and ongoing natural selection among ethnically Tibetan women at high altitude in Nepal. PLoS Genet 14:e1007650

Wang, Xin; Wu, Xingye; Zhang, Zhonglin et al. (2018) Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway. Sci Rep 8:17914

Brown, Hailey M; Biering, Scott B; Zhu, Allen et al. (2018) Demarcation of Viral Shelters Results in Destruction by Membranolytic GTPases: Antiviral Function of Autophagy Proteins and Interferon-Inducible GTPases. Bioessays 40:e1700231

Karrison, Theodore; Kocherginsky, Masha (2018) Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials? Clin Trials 15:178-188

An, Ningfei; Khan, Saira; Imgruet, Molly K et al. (2018) Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS. Blood 131:2682-2697

Trujillo, Jonathan A; Sweis, Randy F; Bao, Riyue et al. (2018) T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol Res 6:990-1000

Zeng, Zongyue; Huang, Bo; Huang, Shifeng et al. (2018) The development of a sensitive fluorescent protein-based transcript reporter for high throughput screening of negative modulators of lncRNAs. Genes Dis 5:62-74

Lee, Ji-Hye; Park, Beom Seok; Han, Kang R et al. (2018) Insight Into the Interaction Between RNA Polymerase and VPg for Murine Norovirus Replication. Front Microbiol 9:1466

Cheng, Jason X; Chen, Li; Li, Yuan et al. (2018) RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia. Nat Commun 9:1163